Medifast (MED) Up 6.5% Since Last Earnings Report: Can It Continue?
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
Medifast Bolsters Growth Through Health & Wellness Solutions
MED is expanding OPTAVIA, digital tools and wellness offerings to drive long-term growth and strengthen customer ties.
Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Daniel R. Chard - Executive Chairman & CEO James P.
Medifast: Coach Surge Fuels Growth
Initiate Medifast with Strong Buy and $56 PT, citing overlooked operational inflection and coach network momentum driving above-consensus FY26 revenue growth. ASCEND product line and digital engagement tools are key catalysts, improving client retention, coach productivity, and setting the stage for a top line comeback. Valuation is anchored on a conservative 1.3x forward P/S multiple, offering asymmetric risk/reward with tangible execution momentum and significant rerating potential.
Medifast (MED) Up 10.9% Since Last Earnings Report: Can It Continue?
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
Medifast Q1 Loss Wider Than Expected, Sales Down 33.8% Y/Y
MED's first-quarter results show challenges from fewer active OPTAVIA Coaches. Nonetheless, the company is focusing on revitalizing its coach base for growth.
Medifast, Inc. (MED) Q1 2025 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q1 2025 Earnings Conference Call April 28, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and CEO Jim Maloney - Chief Financial Officer Nick Johnson - Chief Field Operations Officer Conference Call Participants Jim Salera - Stephens Doug Lane - Water Tower Research Operator Greetings. And welcome to the Medifast First Quarter 2025 Earnings Conference Call.
Medifast to Report Q1 Earnings: What Investors Should Expect
MED's first-quarter results may show challenges in customer acquisition amid market headwinds and shifting consumer trends.
Medifast Trades Near 52-Week Low: What's the Best Move Now?
MED faces steep revenue declines and coach losses but aims to rebound through innovation, marketing and new GLP-1-focused initiatives.
Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect
Medifast, Inc.'s business is deteriorating as GLP-1 medication has lowered demand, causing a vicious flywheel effect as coaches are exiting the platform. The company is trying to reposition itself as a GLP-1 adjacent business, but the repositioning hasn't shown results so far with a deteriorating immediate earnings outlook. MED stock now trades below the company's net cash position, but due to high earnings uncertainty, the low valuation is justified.
MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition
Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.
Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call.
